ProCE Banner Activity

Updates on Emerging HDV Treatments

Clinical Thought

Many promising HDV treatment options are on the horizon, including an entry inhibitor, a prenylation inhibitor, an immunomodulator, and nucleic acid polymers.

Released: February 14, 2023

Expiration: February 13, 2024

Share

Faculty

Nancy Reau

Nancy Reau, MD

Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Faculty Disclosure

Primary Author

Nancy Reau, MD

Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Nancy Reau, MD: consultant/advisor/speaker: AbbVie, Antios, Arbutus, Gilead, Intercept, Salix; research support: AbbVie, Gilead, Intercept.